AstraZeneca, BMS tout diabetes drug's safety, but will it help sales?
This article was originally published in Scrip
Executive Summary
AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza lags rivals for sales but it holds a distinction that its marketers are already attempting to exploit: The therapy is now "among the most extensively studied diabetes medications," the companies say.